A review examines the prevailing theory of cancer evolution. The authors highlight both practical and theoretical limitations of the clonal model of cancer evolution and propose areas for improving ...

Characterizing clonal evolution in blood cancers like acute myeloid leukemia (AML) is critical for understanding their mutational histories and how cell populations change during disease development.

The rarity of thymic epithelial tumors and limited preclinical modeling constrain our understanding of disease biology and the advancement of rational treatment strategies. Tumor mutational profiling ...

Tumor-infiltrating clonal hematopoiesis increased the risk of disease recurrence or death among patients with cancer. TET2 mutations were the strongest genetic predictor of tumor-infiltrating clonal ...

Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort ...

In patients with cancer, clonal hematopoiesis was associated with cardiac toxicity and in increased risk of death due to heart conditions. While prior research has shown that clonal hematopoiesis can ...

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT We ...

About 1 in 5 patients with cancer who undergo genetic testing are incidentally found to have mutations in their blood called ...